Advertisement
Dr. Nelson will assume the role of CEO and Lily Lai, eBioscience'sfounder, will remain as President during a transition period. Nelson will alsojoin eBioscience's Board of Directors.
Advertisement
Dr. Nelson commented: "I'm very excited about joining a fast growingcompany with the reputation and potential of eBioscience. The company'sbreakthrough products and enabling technologies are critical to the future ofbiotechnology and life science research."
Dr. Brian Seed, the Lead Director on eBioscience's Board of Directors,commented: "Todd has exceptional technical, financial and operatingexperience, and the energy and strategic vision to lead eBioscience throughits next stage of growth."
Seed continued: "During Lily's tenure as President, eBioscience has grownfrom a start-up enterprise to a fast growing, profitable company that now hasmore than 1,000 products on the market, and a strong brand within the lifescience research community. We are grateful for her many contributions toeBioscience."
Todd R. Nelson was named Vice President Global Corporate Development andStrategy of Invitrogen Corporation in 2005. In addition to being responsiblefor mergers and acquisitions functions globally, Nelson held primaryresponsibility for the development and implementation of both corporate anddivisional strategies for the organization on a world wide basis. Prior tothat, he was Managing Director and Head, Global Life Sciences CorporateStrategy and Research at RBC Capital Markets, and First Vice President, GlobalCorporate Strategy and Economics at Merrill Lynch in New York.
Dr. Nelson has been a visible figure within the Life Sciences industry.During his more than 15 year tenure in the industry he has been responsiblefor the design and implementation of numerous corporate and operatingstrategies for various companies. In addition, he led the underwritingactivities for more than 30 IPOs and has been involved in numerous valuecreating mergers and acquisitions, together totaling more than $7 billion. Hehas been a founder of several biotechnology companies and currently serves onthe Board of Directors of Lokoya Capital Partners, LLC. Fluoropharma, Inc.,and Blue Heron Biotechnologies, Inc.
Dr. Nelson has a Ph.D. from the University of Minnesota in molecularpathology and received advanced training as a senior fellow in clinicalchemistry and molecular diagnostics at Mayo Clinic. Dr. Nelson received hisMBA from the Carlson School of Business.
About eBioscience
eBioscience, headquartered in San Diego, California provides products andservices that support academic and government research institutions andpharmaceutical and biotech companies worldwide. The company provides essentiallife science technologies for disease research and drug discovery. For moreinformation, visit http://www.ebioscience.com.
SOURCE eBioscience, Inc.
